Antiprogestins in breast cancer treatment: Are we ready?

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages

  Lanari, Claudia ^a   Wargon, Victoria ^a   Rojas, Paola ^a   Molinolo, Alfredo A ^a,b  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; AGLEPRISTONE; ANTIGESTAGEN; ASOPRISNIL; DEXAMETHASONE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LONAPRISAN; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; ONAPRISTONE; ORG 31806; ORG 33628; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROGESTERONE RECEPTOR MODULATOR; PROMEGESTONE; TAMOXIFEN; TELAPRISTONE ACETATE; ULIPRISTAL; UNCLASSIFIED DRUG;

ANOREXIA; APOPTOSIS; BREAST CANCER; BREAST HYPERPLASIA; CANCER CELL CULTURE; CANCER CLASSIFICATION; CYTOSTASIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; HISTOPATHOLOGY; HOT FLUSH; HUMAN; LEIOMYOMA; LETHARGY; LIVER TOXICITY; MENINGIOMA; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; RASH; REVIEW; TREATMENT OUTCOME; TUMOR REGRESSION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HORMONE ANTAGONISTS; HUMANS; RECEPTORS, PROGESTERONE;

EID: 84862646166     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0378     Document Type: Review

References (143)

1. Actis AM, Caruso SP & Levin E 1995 Opposite effect of a cAMP analogue on tumoral growth related to hormone dependence of a murine mammary tumor. Cancer Letters 96 81-85. (doi:10.1016/0304-3835(95)03908-F)
2. Afhuppe W, Sommer A, Muller J, Schwede W, Fuhrmann U & Moller C 2009 Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system. Journal of Steroid Biochemistry and Molecular Biology 113 105-115. (doi:10.1016/j.jsbmb.2008.11.015)
3. Afhuppe W, Beekman JM, Otto C, Korr D, Hoffmann J, Fuhrmann U & Moller C 2010 In vitro characterization of ZK 230211 - a type III progesterone receptor antagonist with enhanced antiproliferative properties. Journal of Steroid Biochemistry and Molecular Biology 119 45-55. (doi:10.1016/j.jsbmb.2009. 12.011)
4. Arruvito L, Giulianelli S, Flores AC, Paladino N, Barboza M, Lanari C & Fainboim L 2008 NK cells expressing a progesterone receptor are susceptible to progesterone-induced apoptosis. Journal of Immunology 180 5746-5753.
5. Attardi BJ, Burgenson J, Hild SA, Reel JR & Blye RP 2002 CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Molecular and Cellular Endocrinology 188 111-123. (doi:10.1016/S0303-7207(01)00743-2)
6. Attardi BJ, Burgenson J, Hild SA & Reel JR 2004 In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. Journal of Steroid Biochemistry and Molecular Biology 88 277-288. (doi:10.1016/j.jsbmb.2003.12.004)
7. Aupperlee M, Kariagina A, Osuch J & Haslam SZ 2005 Progestins and breast cancer. Breast Disease 24 37-57.
8. Bakker GH, Setyono-Han B, Henkelman MS, de Jong FH, Lamberts SW, van der Schoot P & Klijn JG 1987 Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treatment Reports 71 1021-1027. (Pubitemid 18002209)
9. Bakker GH, Setyono-Han B, Portengen H, de Jong FH, Foekens JA & Klijn JG 1989 Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 125 1593-1598. (doi:10.1210/endo-125-3-1593)
10. Bakker GH, Setyono-Han B, Portengen H, de Jong FH, Foekens JA & Klijn JG 1990 Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. Journal of Steroid Biochemistry and Molecular Biology 37 789-794. (doi:10.1016/0960-0760(90)90421-G)
11. Bardon S, Vignon F, Chalbos D & Rochefort H 1985 RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. Journal of Clinical Endocrinology and Metabolism 60 692-697. (doi:10.1210/jcem-60-4-692)
12. Beck CA, Weigel NL, Moyer ML, Nordeen SK & Edwards DP 1993 The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. PNAS 90 4441-4445. (doi:10.1073/pnas.90.10.4441)
13. Benagiano G, Bastianelli C & Farris M 2008 Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opinion on Pharmacotherapy 9 2487-2496. (doi:10.1517/14656566. 9.14.2487)
14. Beral V 2003 Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 419-427. (doi:10.1016/S0140-6736(03)14596-5)
15. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE et al. 2007 Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447 799-816. (doi:10.1038/nature05874)
16. Boonyaratanakornkit V & Edwards DP 2007 Receptor mechanisms mediating non-genomic actions of sex steroids. Seminars in Reproductive Medicine 25 139-153. (doi:10.1055/s-2007-973427)
17. Bottino MC, Cerliani JP, Rojas P, Giulianelli S, Soldati R, Mondillo C, Gorostiaga MA, Pignataro OP, Calvo JC, Gutkind JS et al. 2011 Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid nongenomic effects. Breast Cancer Research and Treatment 126 621-636. (doi:10.1007/s10549-010-0971-3)
18. Bowden RT, Hissom JR & Moore MR 1989 Growth stimulation of T47D human breast cancer cells by the anti-progestin RU486. Endocrinology 124 2642-2644. (doi:10.1210/endo-124-5-2642)
19. Brodie AM, Wing LY, Goss P, Dowsett M & Coombes RC 1986 Aromatase inhibitors and the treatment of breast cancer. Journal of Steroid Biochemistry 24 91-97. (doi:10.1016/0022-4731(86)90037-3)
20. Busia L, Faus H, Hoffmann J & Haendler B 2011 The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression. Molecular and Cellular Endocrinology 333 37-46. (doi:10.1016/j.mce. 2010.11.034)
21. Calaf GM 2006 Susceptibility of human breast epithelial cells in vitro to hormones and drugs. International Journal of Oncology 28 285-295.
22. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF et al. 2006 Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 38 1289-1297. (doi:10.1038/ng1901)
23. Cerliani JP, Giulianelli S, Sahores A, Wargon V, Gongora A, Baldi A, Molinolo A, Lamb CE & Lanari C 2010 Mifepristone inhibits MPA-and FGF2-induced mammary tumor growth but not FGF2-induced mammary hyperplasia. Medicina 70 529-532.
24. Check JH, Dix E, Cohen R, Check D & Wilson C 2010 Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Research 30 623-628.
25. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA et al. 2003 Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. Journal of the American Medical Association 289 3243-3253. (doi:10.1001/jama.289.24.3243)
26. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE et al. 2010 Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. Journal of the American Medical Association 304 1684-1692. (doi:10.1001/jama.2010.1500)
27. Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H &Elger W 2000 Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 65 741-751. (doi:10.1016/S0039-128X(00) 00190-2)
28. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G & Elger W 2005 Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Reviews 26 423-438. (doi:10.1210/er.2005-0001)
29. Clarke CL & Sutherland RL 1990 Progestin regulation of cellular proliferation. Endocrine Reviews 11 266-301. (doi:10.1210/edrv-11-2-266)
30. Conneely OM & Lydon JP 2000 Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 65 571-577. (doi:10.1016/S0039-128X(00) 00115-X)
31. Conneely OM, Jericevic BM & Lydon JP 2003 Progesterone receptors in mammary gland development and tumorigenesis. Journal of Mammary Gland Biology and Neoplasia 8 205-214. (doi:10.1023/A:1025952924864)
32. Dauvois S, White R & Parker MG 1993 The antiestrogen ICI 182 780 disrupts estrogen receptor nucleocytoplasmic shuttling. Journal of Cell Science 106 1377-1388. (Pubitemid 24018422)
33. DeMarzo AM, Beck CA, Onate SA & Edwards DP 1991 Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein. PNAS 88 72-76. (doi:10.1073/pnas.88.1.72)
34. Dran G, Luthy IA,Molinolo AA,Montecchia F, Charreau EH, Pasqualini CD & Lanari C 1995 Effect of medroxyprogesterone acetate (MPA) and serumfactors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma. Breast Cancer Research and Treatment 35 173-186. (doi:10.1007/BF00668207)
35. Dressing GE & Lange CA 2009 Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation. Steroids 74 573-576. (doi:10.1016/j.steroids.2008.12.001)
36. Edwards DP, Altmann M, DeMarzo A, Zhang Y, Weigel NL & Beck CA 1995 Progesterone receptor and the mechanism of action of progesterone antagonists. Journal of Steroid Biochemistry and Molecular Biology 53 449-458. (doi:10.1016/0960-0760(95)00091-D)
37. Engman M, Skoog L, Soderqvist G & Gemzell-Danielsson K 2008 The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Human Reproduction 23 2072-2079. (doi:10.1093/humrep/den228)
38. el Etreby MF, Liang Y, Wrenn RW & Schoenlein PV 1998 Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Research and Treatment 51 149-168. (doi:10.1023/A: 1006078032287)
39. el Etreby MF, Liang Y, Johnson MH & Lewis RW 2000 Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 42 99-106. (doi:10.1002/ (SICI)1097-0045(20000201) 42:2!99::AID-PROS3O3.0.CO;2-I)
40. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240 889-895. (doi:10.1126/science. 3283939)
41. Faivre EJ & Lange CA 2007 Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Molecular and Cellular Biology 27 466-480. (doi:10.1128/MCB.01539-06)
42. Fjelldal R, Moe BT, Orbo A & Sager G 2010 MCF-7 cell apoptosis and cell cycle arrest: non-genomic effects of progesterone and mifepristone (RU-486). Anticancer Research 30 4835-4840.
43. Fuhrmann U, Hess-Stumpp H, Cleve A, Neef G, Schwede W, Hoffmann J, Fritzemeier KH & Chwalisz K 2000 Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. Journal of Medicinal Chemistry 43 5010-5016. (doi:10.1021/jm001000c)
44. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG &Schoenlein PV 2004 Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clinical Cancer Research 10 5215-5225. (doi:10.1158/1078-0432.CCR-03-0637)
45. Gaillard RC, Riondel A, Muller AF, Herrmann W & Baulieu EE 1984 RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. PNAS 81 3879-3882. (doi:10.1073/pnas.81.12.3879)
46. Galac S, Kooistra HS, Dieleman SJ, Cestnik V & Okkens AC 2004 Effects of aglepristone, a progesterone receptor antagonist, administered during the early luteal phase in non-pregnant bitches. Theriogenology 62 494-500. (doi:10.1016/j.theriogenology.2003.11.004)
47. Giulianelli S, Cerliani JP, Lamb CA, Fabris VT, Bottino MC, Gorostiaga MA, Novaro V, Gongora A, Baldi A, Molinolo A et al. 2008 Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: a role for the FGF-2/FGFR-2 axis. International Journal of Cancer 123 2518-2531. (doi:10.1002/ijc.23802)
48. Goyeneche AA, Caron RW & Telleria CM 2007 Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clinical Cancer Research 13 3370-3379. (doi:10.1158/1078-0432.CCR-07-0164)
49. Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM & Clarke CL 1995 Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Research 55 5063-5068.
50. Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM &Clarke CL 2005 Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Molecular Endocrinology 19 2713-2735. (doi:10.1210/me.2005-0126)
51. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L & Stevenson LL 1991 Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. Journal of Neurosurgery 74 861-866. (doi:10.3171/jns.1991.74.6.0861)
52. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A & Sitruk-Ware R 2006 Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Investigation 24 727-733. (doi:10.1080/07357900601062339)
53. Gruol DJ, Zee MC, Trotter J & Bourgeois S 1994 Reversal of multidrug resistance by RU 486. Cancer Research 54 3088-3091. (Pubitemid 24208906)
54. Hagan CR, Faivre EJ & Lange CA 2009 Scaffolding actions of membrane-associated progesterone receptors. Steroids 74 568-572. (doi:10.1016/j.steroids.2008.12.004)
55. Han SJ, Tsai SY, Tsai MJ & O'Malley BW 2007 Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice. Endocrinology 148 2471-2486. (doi:10.1210/en. 2006-1561)
56. Helguero LA, Viegas M, Asaithamby A, Shyamala G, Lanari C & Molinolo AA 2003 Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment. Breast Cancer Research and Treatment 79 379-390. (doi:10.1023/A:1024029826248)
57. Herrman W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E & Baulieu EE 1982 Effects of an anti-progestin steroid in women: interruption of the menstrual cycle or early pregnancy (author's transl). Contraception FertilitéSexualité 10 389-393. (Pubitemid 13239309)
58. Hild SA, Reel JR, Hoffman LH & Blye RP 2000 CDB-2914: anti-progestational/anti-glucocorticoid profile and postcoital anti-fertility activity in rats and rabbits. Human Reproduction 15 822-829. (doi:10.1093/humrep/15.4.822)
59. Hissom JR & Moore MR 1987 Progestin effects on growth in the human breast cancer cell line T-47D - possible therapeutic implications. Biochemical and Biophysical Research Communications 145 706-711. (doi:10.1016/ 0006-291X(87)91022-9)
60. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB & Fuqua SA 2004 Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clinical Cancer Research 10 2751-2760. (doi:10.1158/1078-0432.CCR-03-0141)
61. Horwitz KB 1987 The structure and function of progesterone receptors in breast cancer. Journal of Steroid Biochemistry 27 447-457. (doi:10.1016/0022- 4731(87)90339-6)
62. Horwitz KB 2008 The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Molecular Endocrinology 22 2743-2750. (doi:10.1210/me.2008-0291)
63. Horwitz KB & McGuire WL 1975 Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189 726-727. (doi:10.1126/ science.168640)
64. Horwitz KB, Koseki Y & McGuire WL 1978 Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103 1742-1751. (doi:10.1210/endo-103-5-1742)
65. Horwitz KB, Mockus MB & Lessey BA 1982 Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell 28 633-642. (doi:10.1016/0092-8674 (82)90218-5)
66. Hyder SM, Murthy L & Stancel GM 1998 Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Research 58 392-395.
67. Hyder SM, Liang Y, Wu J & Welbern V 2009 Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells. Endocrine-Related Cancer 16 809-817. (doi:10.1677/ERC-08-0311)
68. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L &Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Molecular Endocrinology 11 693-705. (doi:10.1210/me.11.6.693)
69. Jacobsen BM, Richer JK, Schittone SA & Horwitz KB 2002 New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. Journal of Biological Chemistry 277 27793-27800. (doi:10.1074/jbc.M202584200)
70. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
71. Jeng MH, Langan-Fahey SM & Jordan VC 1993 Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Endocrinology 132 2622-2630. (doi:10.1210/en.132.6.2622)
72. Jordan VC 1990 Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Research and Treatment 15 125-136. (doi:10.1007/BF01806350)
73. Jordan VC 2008 The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer - survival or death? Journal of Clinical Oncology 26 3073-3082. (doi:10.1200/JCO.2008.17.5190)
74. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H & Chambon P 1990 Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO Journal 9 1603-1614.
75. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S & Brenner HJ 1979 Establishment and characterization of a cell line of human breast carcinoma origin. European Journal of Cancer 15 659-670. (doi:10.1016/0014-2964(79)90139-7)
76. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ & Alexieva-Figusch J 1989 Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Research 49 2851-2856. (Pubitemid 19148614)
77. Klijn JG, Setyono-Han B, Sander HJ, Lamberts SW, de Jong FH, Deckers GH & Foekens JA 1994 Pre-clinical and clinical treatment of breast cancer with antiprogestins. Human Reproduction 9 (Suppl 1) 181-189. (Pubitemid 24203940)
78. Klijn JG, Setyono-Han B & Foekens JA 2000 Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65 825-830. (doi:10.1016/S0039-128X(00)00195-1)
79. Kloosterboer HJ, Deckers GH, Schoonen WG, Hanssen RG, Rose UM, Verbost PM, Hsiu JG, Williams RF & Hodgen GD 2000 Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 65 733-740. (doi:10.1016/S0039-128X(00)00189-6)
80. Kordon E, Lanari C, Meiss R, Charreau E & Pasqualini CD 1990 Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Research and Treatment 17 33-43. (doi:10.1007/BF01812682)
81. Lamb C, Simian M, Molinolo A, Pazos P & Lanari C 1999 Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation. Journal of Steroid Biochemistry and Molecular Biology 70 133-142. (doi:10.1016/S0960-0760(99)00108-9)
82. Lamb CA, Helguero LA, Giulianelli S, Soldati R, Vanzulli SI, Molinolo A & Lanari C 2005 Antisense oligonucleotides targeting the progesterone receptor inhibit hormone-independent breast cancer growth in mice. Breast Cancer Research and Treatment 7 R1111-R1121.
83. Lanari C, Molinolo AA & Pasqualini CD 1986 Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Letters 33 215-223. (doi:10.1016/0304-3835(86)90027-3)
84. Lanari C, Kordon E, Molinolo A, Pasqualini CD & Charreau EH 1989 Mammary adenocarcinomas induced by medroxyprogesterone acetate: hormone dependence and EGF receptors of BALB/c in vivo sublines. International Journal of Cancer 43 845-850. (doi:10.1002/ijc.2910430518)
85. Lanari C, Lamb C, Fabris V, Helguero L, Soldati R, Bottino M, Giulianelli S, Cerliani J, Wargon V & Molinolo A 2009 The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocrine-Related Cancer 16 333-350. (doi:10.1677/ERC-08-0244)
86. Lange CA, Shen T & Horwitz KB 2000 Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. PNAS 97 1032-1037. (doi:10.1073/pnas.97.3.1032)
87. Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB & Jacobsen BM 2008 Progesterone receptor action: translating studies in breast cancer models to clinical insights. Advances in Experimental Medicine and Biology 630 94-111.
88. Lecureur V, Fardel O & Guillouzo A 1994 The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Letters 355 187-191. (doi:10.1016/0014-5793(94)01186-9)
89. Leonhardt SA, Boonyaratanakornkit V & Edwards DP 2003 Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids 68 761-770. (doi:10.1016/S0039-128X(03)00129-6)
90. Li X & O'Malley BW 2003 Unfolding the action of progesterone receptors. Journal of Biological Chemistry 278 39261-39264. (doi:10.1074/jbc. R300024200)
91. Li M, Spitzer E, Zschiesche W, Binas B, Parczyk K & Grosse R 1995 Antiprogestins inhibit growth and stimulate differentiation in the normal mammary gland. Journal of Cellular Physiology 164 1-8. (doi:10.1002/jcp. 1041640102)
92. Liang Y, Wu J, Stancel GM & Hyder SM 2005 p53- dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 93 173-182. (doi:10.1016/j.jsbmb. 2004.12.011)
93. Liang Y, Besch-Williford C, Brekken RA & Hyder SM 2007 Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Research 67 9929-9936. (doi:10.1158/0008-5472.CAN-07-1103)
94. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM & O'Malley BW 1995 Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes and Development 9 2266-2278. (doi:10.1101/gad.9.18.2266)
95. McGuire WL 1975 Endocrine therapy of breast cancer. Annual Review of Medicine 26 353-363. (doi:10.1146/annurev.me.26.020175.002033)
96. Meyer ME, Pornon A, Ji JW, Bocquel MT, Chambon P &Gronemeyer H 1990 Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO Journal 9 3923-3932.
97. Michna H, Schneider MR, Nishino Y & el Etreby MF 1989 Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Research and Treatment 14 275-288. (doi:10.1007/BF01806299)
98. Michna H, Schneider M, Nishino Y, el Etreby MF &McGuire WL 1990 Progesterone antagonists block the growth of experimental mammary tumors in G0/G1. Breast Cancer Research and Treatment 17 155-156. (doi:10.1007/BF01806296)
99. Molinolo AA, Lanari C, Charreau EH, Sanjuan N &Pasqualini CD 1987 Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. Journal of the National Cancer Institute 79 1341-1350. (Pubitemid 18036740)
100. Montecchia MF, Lamb C, Molinolo AA, Luthy IA, Pazos P, Charreau E, Vanzulli S & Lanari C 1999 Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas. Journal of Steroid Biochemistry and Molecular Biology 68 11-21. (doi:10.1016/S0960-0760(98)00166-6)
101. Moore MR 2004 A rationale for inhibiting progesterone-related pathways to combat breast cancer. Current Cancer Drug Targets 4 183-189. (doi:10.2174/1568009043481515)
102. Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA & Clarke CL 2004 Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes, Chromosomes & Cancer 39 236-248. (doi:10.1002/gcc.10321)
103. Mote PA, Graham JD & Clarke CL 2007 Progesterone receptor isoforms in normal and malignant breast. Ernst Schering Foundation Symposium Proceedings 77-107. (doi:10.1007/2789-2008-076)
104. Mulac-Jericevic B, Lydon JP, DeMayo FJ & Conneely OM 2003 Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. PNAS 100 9744-9749. (doi:10.1073/pnas.1732707100)
105. Muphung W, Rungsipipat A & Chatdarong K 2009 Effects of the anti-progestin aglepristone on the uterine tissue of cats administered medroxyprogesterone acetate. Reproduction in Domestic Animals 44 (Suppl 2) 204-207. (doi:10.1111/ j.1439-0531.2009.01411.x)
106. Nishino T, Ishibashi K, Hirtreiter C & Nishino Y 2009 Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone. Journal of Steroid Biochemistry and Molecular Biology 116 187-190. (doi:10.1016/j.jsbmb.2009.05.013)
107. Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP & Oesterreich S 2011 Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clinical Cancer Research 17 4177-4186. (doi:10.1158/1078-0432.CCR-10-2950)
108. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T & Fisher B 1996 Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. Journal of Clinical Oncology 14 2709-2712. (Pubitemid 26329656)
109. Petz LN & Nardulli AM 2000 Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Molecular Endocrinology 14 972-985. (doi:10.1210/me.14.7.972)
110. Petz LN, Ziegler YS, Loven MA & Nardulli AM 2002 Estrogen receptor alpha and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells. Endocrinology 143 4583-4591. (doi:10.1210/en.2002-220369)
111. Polisca A, Scotti L, Orlandi R, Brecchia G, Maranesi M, Zerani M & Boiti C 2010 Aglepristone (RU534) administration to non-pregnant bitches in the mid-luteal phase induces early luteal regression. Theriogenology 74 672-681. (doi:10.1016/j.theriogenology.2010.03.021)
112. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH & Lee EY 2006 Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314 1467-1470. (doi:10.1126/science.1130471)
113. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X & Perou CM 2010 Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research 12 R68. (doi:10.1186/bcr2635)
114. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM & Horwitz KB 2002 Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. Journal of Biological Chemistry 277 5209-5218. (doi:10.1074/jbc.M110090200)
115. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, FrahmI, Sapia S, Brouckaert P et al. 2008 TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Experimental Cell Research 314 509-529. (doi:10.1016/j.yexcr.2007.10.005)
116. Robertson JF, Willsher PC, Winterbottom L, Blamey RW &Thorpe S 1999 Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. European Journal of Cancer 35 214-218. (doi:10.1016/S0959-8049(98)00388-8)
117. Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S & Rochefort H 1987 The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bulletin du Cancer 74 455-461. (Pubitemid 17135278)
118. Santen R, Cavalieri E, Rogan E, Russo J, Guttenplan J, Ingle J & Yue W 2009 Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects. Annals of the New York Academy of Sciences 1155 132-140. (doi:10.1111/j.1749-6632.2008.03685.x)
119. Sartorius CA, Tung L, Takimoto GS & Horwitz KB 1993 Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. Journal of Biological Chemistry 268 9262-9266. (Pubitemid 23145969)
120. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS & Horwitz KB 1994 New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Research 54 3868-3877. (Pubitemid 24241209)
121. Scarpin KM, Graham JD, Mote PA & Clarke CL 2009 Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nuclear Receptor Signaling 7 e009.
122. Schneider MR, Michna H, Nishino Y, Neef G & el Etreby MF 1990 Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors. Anticancer Research 10 683-687. (Pubitemid 20237817)
123. Schneider W, Ramachandran C, Satyaswaroop PG &Shyamala G 1991 Murine progesterone receptor exists predominantly as the 83-kilodalton 'A' form. Journal of Steroid Biochemistry and Molecular Biology 38 285-291. (doi:10.1016/0960-0760(91)90099-Q)
124. Schultz JR, Petz LN & Nardulli AM 2003 Estrogen receptor alpha and Sp1 regulate progesterone receptor gene expression. Molecular and Cellular Endocrinology 201 165-175. (doi:10.1016/S0303-7207(02)00415-X)
125. Sheridan PL, Krett NL, Gordon JA & Horwitz KB 1988 Human progesterone receptor transformation and nuclear down-regulation are independent of phosphorylation. Molecular Endocrinology 2 1329-1342. (doi:10.1210/mend-2-12- 1329)
126. Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH &Dale E 1998 Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. PNAS 95 696-701. (doi:10.1073/pnas.95.2.696)
127. Simian M, Molinolo A & Lanari C 2006 Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. American Journal of Pathology 168 270-279. (doi:10.2353/ajpath.2006.050012)
128. Simian M, Bissell MJ, Barcellos-Hoff MH & Shyamala G 2009 Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice. Breast Cancer Research 11 R72. (doi:10.1186/bcr2408)
129. Skafar DF 1991 Differences in the binding mechanism of RU486 and progesterone to the progesterone receptor. Biochemistry 30 10829-10832. (doi:10.1021/bi00109a003)
130. Skildum A, Faivre E & Lange CA 2005 Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Molecular Endocrinology 19 327-339. (Pubitemid 40223458)
131. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H & Sitruk-Ware R 2005 Management of patients receiving long-term treatment with mifepristone. Fertility and Sterility 84 1719-1726. (doi:10.1016/j.fertnstert. 2005.05.056)
132. Takimoto GS, Hovland AR, Tasset DM, Melville MY, Tung L & Horwitz KB 1996 Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors. Journal of Biological Chemistry 271 13308-13316. (doi:10.1074/jbc.271.23.13308)
133. Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT &Telleria CM 2011 Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and nonreproductive origin regardless of progesterone receptor expression. BMC Cancer 11 207. (doi:10.1186/1471-2407-11-207)
134. Ulmann A & Dubois C 1988 Anti-progesterones in obstetrics, ectopic pregnancies and gynaecological malignancy. Baillière's Clinical Obstetrics and Gynaecology 2 631-638. (doi:10.1016/S0950-3552(88)80049-X)
135. Vanzulli S, Efeyan A, Benavides F, Helguero L, Peters G, Shen J, Conti CJ, Lanari C & Molinolo A 2002 p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis 23 749-757. (doi:10.1093/carcin/23.5.749)
136. Vanzulli SI, Soldati R, Meiss R, Colombo L, Molinolo AA &Lanari C 2005 Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression. Carcinogenesis 26 1055-1063. (doi:10.1093/carcin/bgi060)
137. Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V et al. 2009 CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiology, Biomarkers & Prevention 18 901-914. (doi:10.1158/1055-9965. EPI-08-0875)
138. Vignon F, Bardon S, Chalbos D & Rochefort H 1983 Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. Journal of Clinical Endocrinology and Metabolism 56 1124-1130. (doi:10.1210/jcem-56-6-1124)
139. Wargon V, Helguero LA, Bolado J, Rojas P, Novaro V, Molinolo A & Lanari C 2009 Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. Breast Cancer Research and Treatment 116 449-460. (doi:10.1007/s10549-008-0150-y)
140. Wargon V, Fernandez SV, Goin M, Giulianelli S, Russo J &Lanari C 2011 Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. Breast Cancer Research and Treatment 126 319-332. (doi:10.1007/s10549-010-0908-x)
141. Wiehle R, Lantvit D, Yamada T & Christov K 2011 CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis. Cancer Prevention Research 4 414-424. (doi:10.1158/1940-6207.CAPR-10-0244)
142. Women's Health 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 288 321-333. (doi:10.1001/jama.288.3.321)
143. Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, Sasaki H, Morikawa A & Maruo T 2010 Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Seminars in Reproductive Medicine 28 260-273. (doi:10.1055/s-0030-1251483)